Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03073525 · ClinicalTrials.gov registry record · Phase 2
A Trial of Atezolizumab and Vigil in Patients With Advanced Gynecological Cancers
A Phase 2 study, sponsored by Gradalis.
- Completed
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
NCT03073525 is a Phase 2 study that has completed, run by Gradalis. The registered enrollment target is 25 participants.
The verdict
NCT03073525, a Phase 2 study, has completed, sponsored by Gradalis.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
Study Summary
The clinical trial was a companion study to protocol CL-PTL-119 (A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of Vigil Engineered Autologous Tumor Cell Immunotherapy in Subjects with Stage IIIb-IV Ovarian Cancer in Clinical Complete Response following Surgery and Primary Chemotherapy (VITAL) NCT02346747). Participants who had investigational product (Vigil) successfully made but were not eligible to enroll onto the VITAL study or previously randomized to placebo were given the opportunity to participate in this protocol. The main goal of this clinical trial was to determine the safety of combining Vigil therapy with atezolizumab.
Interventions
- DRUG Atezolizumab
- BIOLOGICAL Vigil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2017-05-31 |
| Est. Completion | 2022-05-18 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03073525
The ClinicalTrials.gov registry entry for NCT03073525 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gradalis, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Atezolizumab is the first listed.
NCT03073525 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03073525 about?
NCT03073525 is a clinical study titled "A Trial of Atezolizumab and Vigil in Patients With Advanced Gynecological Cancers". The clinical trial was a companion study to protocol CL-PTL-119 (A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of Vigil Engineered Autologous Tumor Cell Immunotherapy in Subjects with Stage IIIb-IV Ovarian Cancer in Clinical Complete Response following Surgery and Primary Chemotherapy...
What is the current status of trial NCT03073525?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2017-05-31. Estimated completion is 2022-05-18.
What interventions are being tested in trial NCT03073525?
The interventions under investigation include: Atezolizumab (DRUG), Vigil (BIOLOGICAL).
Who is sponsoring clinical trial NCT03073525?
This trial is sponsored by Gradalis, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.